Relationship between increased maternal serum free human chorionic gonadotropin levels in the second trimester and adverse pregnancy outcomes: a retrospective cohort study.
Humans
Pregnancy
Female
Retrospective Studies
Pregnancy Trimester, Second
/ blood
Adult
Pregnancy Outcome
/ epidemiology
Chorionic Gonadotropin, beta Subunit, Human
/ blood
Pregnancy Complications
/ blood
China
/ epidemiology
Pre-Eclampsia
/ blood
Cohort Studies
Polyhydramnios
/ blood
Chorionic Gonadotropin
/ blood
Hyperlipidemias
/ blood
Adverse pregnancy outcomes
Free beta-subunit human chorionic gonadotropin
Maternal serum
Retrospective cohort study
Risk ratios
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
07
05
2023
accepted:
22
04
2024
medline:
5
6
2024
pubmed:
5
6
2024
entrez:
4
6
2024
Statut:
epublish
Résumé
A retrospective cohort study was conducted to collect the data of pregnant women who received hospital delivery in Hangzhou Women's Hospital from January 2018 to December 2020, and who participated in the second trimester (15-20 We retrospectively analyzed the clinical data of 1,978 women in the elevated maternal serum free β-hCG group (free β-hCG ≥ 2.50 multiples of the median, MoM) and 20,767 women in the normal group (0.25 MoM ≤ free β-hCG < 2.50 MoM) from a total of 22,745 singleton pregnancies, and modified Poisson regression analysis was used to calculate risk ratios (RRs) and 95% confidence intervals (CI) of the two groups. The gravidity and parity in the elevated free β-hCG group were lower, and the differences between the groups were statistically significant (all, P < 0.05). The risks of polyhydramnios, preeclampsia, and hyperlipidemia, were increased in women with elevated free β-hCG levels (RRs: 1.996, 95% CI: 1.322-3.014; 1.469, 95% CI: 1.130-1.911 and 1.257, 95% CI: 1.029-1.535, respectively, all P < 0.05), intrauterine growth restriction (IUGR) and female infants were also likely to happen (RRs = 1.641, 95% CI: 1.103-2.443 and 1.101, 95% CI: 1.011-1.198, both P < 0.05). Additionally, there was an association between elevated AFP and free β-hCG levels in second-trimester (RR = 1.211, 95% CI: 1.121-1.307, P < 0.001). APOs, such as polyhydramnios, preeclampsia, and hyperlipidemia, were increased risks of elevated free β-hCG levels, IUGR and female infants were also likely to happen. Furthermore, there was an association between elevated AFP levels and elevated free β-hCG levels in second-trimester. We recommend prenatal monitoring according to the elevated maternal serum free β-hCG level and the occurrence of APO.
Sections du résumé
BACKGROUND
BACKGROUND
A retrospective cohort study was conducted to collect the data of pregnant women who received hospital delivery in Hangzhou Women's Hospital from January 2018 to December 2020, and who participated in the second trimester (15-20
METHODS
METHODS
We retrospectively analyzed the clinical data of 1,978 women in the elevated maternal serum free β-hCG group (free β-hCG ≥ 2.50 multiples of the median, MoM) and 20,767 women in the normal group (0.25 MoM ≤ free β-hCG < 2.50 MoM) from a total of 22,745 singleton pregnancies, and modified Poisson regression analysis was used to calculate risk ratios (RRs) and 95% confidence intervals (CI) of the two groups.
RESULTS
RESULTS
The gravidity and parity in the elevated free β-hCG group were lower, and the differences between the groups were statistically significant (all, P < 0.05). The risks of polyhydramnios, preeclampsia, and hyperlipidemia, were increased in women with elevated free β-hCG levels (RRs: 1.996, 95% CI: 1.322-3.014; 1.469, 95% CI: 1.130-1.911 and 1.257, 95% CI: 1.029-1.535, respectively, all P < 0.05), intrauterine growth restriction (IUGR) and female infants were also likely to happen (RRs = 1.641, 95% CI: 1.103-2.443 and 1.101, 95% CI: 1.011-1.198, both P < 0.05). Additionally, there was an association between elevated AFP and free β-hCG levels in second-trimester (RR = 1.211, 95% CI: 1.121-1.307, P < 0.001).
CONCLUSIONS
CONCLUSIONS
APOs, such as polyhydramnios, preeclampsia, and hyperlipidemia, were increased risks of elevated free β-hCG levels, IUGR and female infants were also likely to happen. Furthermore, there was an association between elevated AFP levels and elevated free β-hCG levels in second-trimester. We recommend prenatal monitoring according to the elevated maternal serum free β-hCG level and the occurrence of APO.
Identifiants
pubmed: 38835013
doi: 10.1186/s12905-024-03105-z
pii: 10.1186/s12905-024-03105-z
doi:
Substances chimiques
Chorionic Gonadotropin, beta Subunit, Human
0
Chorionic Gonadotropin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
323Subventions
Organisme : Zhejiang Medicine and Health Scientific Research Project
ID : 2021KY258
Organisme : The Joint Fund Project of Zhejiang Provincial Natural Science Foundation of China
ID : LBY23H200009
Informations de copyright
© 2024. The Author(s).
Références
D’Hauterive SP, Close R, Gridelet V, Mawet M, Nisolle M, Geenen V. Human Chorionic gonadotropin and early embryogenesis: Review. Int J Mol Sci. 2022;23(3):1380: 1-16.
Ogino MH, Tadi P. Physiology, chorionic gonadotropin. 2022.
Friis PJ, Friis-Hansen LJ, Jensen AK, Nyboe AA, Lokkegaard E. Early pregnancy reference intervals; 29 serum analytes from 4 to 12 weeks’ gestation in naturally conceived and uncomplicated pregnancies resulting in live births. Clin Chem Lab Med. 2019;57(12):1956–67.
doi: 10.1515/cclm-2019-0495
Chen Y, Wang X, Chen Y, Ning W, Chen L, Yin Y, et al. Construction and predictive value of risk models of maternal serum alpha-fetoprotein variants and fetal open neural tube defects. Exp Biol Med (Maywood). 2022;247:822–31.
doi: 10.1177/15353702221080458
pubmed: 35238224
Chen Y, Wang X, Li L, Lu S, Zhang Z. New cut-off values for screening of trisomy 21, 18 and open neural tube defects (ONTD) during the second trimester in pregnant women with advanced maternal age. BMC Pregnancy Childbirth. 2020;20(1):776.
doi: 10.1186/s12884-020-03464-z
pubmed: 33317474
pmcid: 7734716
Chen Y, Chen Y, Shi Y, Ning W, Wang X, Li L, et al. External quality assessment of maternal serum levels of alpha-fetoprotein, free beta-human chorionic gonadotropin, and unconjugated estriol in detecting Down syndrome and neural tube defects in the second trimester of 87 maternal serum samples, based on 105–139 days. Med Sci Monit. 2022;28:e935573.
doi: 10.12659/MSM.935573
pubmed: 35414638
pmcid: 9014801
Ozdemir S, Sahin O, Acar Z, Demir GZ, Ermin E, Aydin A. Prediction of pregnancy complications with maternal biochemical markers used in Down syndrome screening. Cureus. 2022;14(3):e23115.
pubmed: 35425672
pmcid: 9003626
Soni S, Krantz DA, Blitz MJ, Vohra N, Rochelson B. Elevated maternal serum-free beta-human chorionic gonadotropin (beta-hCG) and reduced risk of spontaneous preterm delivery. J Matern Fetal Neonatal Med. 2019;32(19):3191–6.
doi: 10.1080/14767058.2018.1459554
pubmed: 29642747
Parry S, Carper BA, Grobman WA, Wapner RJ, Chung JH, Haas DM, et al. Placental protein levels in maternal serum are associated with adverse pregnancy outcomes in nulliparous patients. Am J Obstet Gynecol. 2022;227(3):497.e1-497.e13.
doi: 10.1016/j.ajog.2022.03.064
pubmed: 35487327
pmcid: 9420814
Taher SI, Alalaf SK. Association between serum beta-human chorionic gonadotropin and preeclampsia and its effects on perinatal and maternal outcomes: a case control study. Arch Gynecol Obstet. 2019;299(3):713–8.
doi: 10.1007/s00404-019-05041-y
pubmed: 30706180
Gagnon A, Wilson RD. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can. 2008;30(10):918–32.
doi: 10.1016/S1701-2163(16)32973-5
pubmed: 19038077
Dai X, Zhang H, Wu B, Ning W, Chen Y, Chen Y. Correlation between elevated maternal serum alpha-fetoprotein and ischemic placental disease: a retrospective cohort study. Clin Exp Hypertens. 2023;45(1):2175848.
Chinese Medical Association Obstetrics and Gynecology Branch Pregnancy Hypertension Disease Group. Guidelines for diagnosis and treatment of hypertension during pregnancy (2015). Chin J Obstet Gynecol. 2015;50:721–8. [Artile in Chinese].
Department of Obstetrics and Gynecology, Chinese Medical Association. Guidelines for diagnosis and treatment of intrahepatic cholestasis of pregnancy. Chinese J Obstet Gynecol. 2015;2015(7):5.
Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676–82.
doi: 10.2337/dc09-1848
pubmed: 20190296
Ehsanipoor R. Premature rupture of membranes: ACOG Practice Bulletin, Number 139. Obstet Gynecol. 2013;122(4):918–30.
doi: 10.1097/01.AOG.0000435415.21944.8f
Jiang C, Wen H, Hu T, Liu Y, Dai X, Chen Y. Perinatal characteristics and pregnancy outcomes of advanced maternal age women with gestational diabetes mellitus: a retrospective cohort study. Health Sci Rep. 2024;7(2):e1903.
Saller DJ, Canick JA, Oyer CE. The detection of non-immune hydrops through second-trimester maternal serum screening. Prenat Diagn. 1996;16(5):431–5.
doi: 10.1002/(SICI)1097-0223(199605)16:5<431::AID-PD877>3.0.CO;2-V
pubmed: 8844001
Bashiri A, Maymon E, Wiznitzer A, Maor E, Mazor M. Chorioangioma of the placenta in association with early severe polyhydramnios and elevated maternal serum HCG: a case report. Eur J Obstet Gynecol Reprod Biol. 1998;79(1):103–5.
doi: 10.1016/S0301-2115(98)00041-4
pubmed: 9643414
Cen J, Lv L, Wei Y, Deng L, Huang L, Deng X, et al. Comparative proteome analysis of amniotic fluids and placentas from patients with idiopathic polyhydramnios. Placenta. 2020;1(89):67–77.
doi: 10.1016/j.placenta.2019.10.010
Tashfeen K, Hamdi IM. Polyhydramnios as a predictor of adverse pregnancy outcomes. Sultan Qaboos Univ Med J. 2013;13(1):57–62.
doi: 10.12816/0003196
pubmed: 23573383
pmcid: 3616801
Glowska-Ciemny J, Szymanski M, Pankiewicz J, Malewski Z, von Kaisenberg C, Kocylowski R. Influence of selected factors on serum AFP levels in pregnant women in terms of prenatal screening accuracy - literature review. Ginekol Pol. 2023;94(2):158–66.
doi: 10.5603/GP.a2022.0148
pubmed: 36597745
Guibourdenche J, Leguy MC, Pidoux G, Hebert-Schuster M, Laguillier C, Anselem O, et al. Biochemical screening for fetal trisomy 21: pathophysiology of maternal serum markers and involvement of the placenta. Int J Mol Sci. 2023;24(8):7669.
doi: 10.3390/ijms24087669
pubmed: 37108840
pmcid: 10146970
Berndt S, Blacher S, Munaut C, Detilleux J, Perrier d’Hauterive S, Huhtaniemi I, et al. Hyperglycosylated human chorionic gonadotropin stimulates angiogenesis through TGF-β receptor activation. FASEB J. 2013;27(4):1309–21.
doi: 10.1096/fj.12-213686
pubmed: 23233533
Butler SA, Luttoo J, Freire MO, Abban TK, Borrelli PT, Iles RK. Human chorionic gonadotropin (hCG) in the secretome of cultured embryos: hyperglycosylated hCG and hCG-free beta subunit are potential markers for infertility management and treatment. Reprod Sci. 2013;20(9):1038–45.
doi: 10.1177/1933719112472739
pubmed: 23439616
Tancrede S, Bujold E, Giguere Y, Renald MH, Girouard J, Forest JC. Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes. J Obstet Gynaecol Can. 2015;37(2):111–6.
doi: 10.1016/S1701-2163(15)30331-5
pubmed: 25767942
Dimitrova V, Chernev T, Vragaleva S, Sluncheva B, Mikhailova E, Kremenski I, Simeonov E. Pregnancy complications with abnormal results of biochemical screening for Down syndrome in second trimester and normal fetal karyotype. Akush Ginekol (Sofiia). 2002;41(6):3–12.
pubmed: 12577497
Kiyokoba R, Uchiumi T, Yagi M, Toshima T, Tsukahara S, Fujita Y, et al. Mitochondrial dysfunction-induced high hCG associated with development of fetal growth restriction and pre-eclampsia with fetal growth restriction. Sci Rep. 2022;12(1):4056.
doi: 10.1038/s41598-022-07893-y
pubmed: 35260712
pmcid: 8904547
Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A. Second trimester biochemical markers as possible predictors of pathological placentation: a retrospective case-control study. Fetal Diagn Ther. 2019;46(3):187–92.
doi: 10.1159/000492829
pubmed: 30726846
Boonpiam R, Wanapirak C, Sirichotiyakul S, Sekararithi R, Traisrisilp K, Tongsong T. Quad test for fetal aneuploidy screening as a predictor of small-for-gestational age fetuses: a population-based study. BMC Pregnancy Childbirth. 2020;20(1):621.
doi: 10.1186/s12884-020-03298-9
pubmed: 33059628
pmcid: 7559175
Li Dongmei. The correlation between maternal serum free β-HCG levels and adverse pregnancy outcomes in mid-pregnancy. Kunming: Master, Kunming Medical College; 2010.
Li D, Zhao F, Zhang Y, Zhu B, Dong X, Su J, Yin Y. The correlation between the high level of serum free β-HCG in the mother during the middle pregnancy and the adverse pregnancy outcomes was studied. Prog Mod Obstet Gynecol. 2011;20(03):186–9.
Yan S. Predictive value of serum AFP and β-hCG for adverse pregnancy outcomes in pregnant women with midtrimester screening. Master: Suzhou University; 2020.
Liao Y, Chen M, Han Z, Han D, et al. The relationship between human chorionic gonadotrophin and lipoprotein metabolism. Hua Xi Yi Ke Da Xue Xue Bao. 1996;27(2):122–5.
pubmed: 9389023
Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Den Hof M. Unexplained elevated maternal serum alpha-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol. 2003;189(3):775–81.
doi: 10.1067/S0002-9378(03)00769-5
pubmed: 14526312
Salim R, Okopnik M, Garmi G, Nachum Z, Zafran N, Shalev E. Lack of association between unexplained elevated maternal serum alpha fetoprotein and/or human chorionic gonadotropin and the occurrence of placental thrombotic lesions. Placenta. 2010;31(4):277–81.
doi: 10.1016/j.placenta.2010.01.010
pubmed: 20132984
Alkazaleh F, Chaddha V, Viero S, Malik A, Anastasiades C, Sroka H, et al. Second-trimester prediction of severe placental complications in women with combined elevations in alpha-fetoprotein and human chorionic gonadotrophin. Am J Obstet Gynecol. 2006;194(3):821–7.
doi: 10.1016/j.ajog.2005.09.010
pubmed: 16522419
Younesi S, Eslamian L, Khalafi N, Taheri AM, Saadati P, Jamali S, et al. Extreme beta HCG levels in first trimester screening are risk factors for adverse maternal and fetal outcomes. Sci Rep. 2023;13(1):1228.
doi: 10.1038/s41598-023-28561-9
pubmed: 36681713
pmcid: 9867730